Pages with the fewest revisions

Jump to navigation Jump to search

Showing below up to 500 results in range #251 to #750.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. Non-homologous end joining‏‎ (1 revision)
  2. Optimisation of protection‏‎ (1 revision)
  3. Attributable risk‏‎ (1 revision)
  4. ICRP Publication 101‏‎ (1 revision)
  5. Best available techniques‏‎ (1 revision)
  6. ICRP Publication 113‏‎ (1 revision)
  7. Bronchiolar region‏‎ (1 revision)
  8. Quasi-threshold dose‏‎ (1 revision)
  9. ICRP Publication 128‏‎ (1 revision)
  10. ICRP Publication 142‏‎ (1 revision)
  11. Compartment‏‎ (1 revision)
  12. Radon progeny‏‎ (1 revision)
  13. ICRP Publication 17‏‎ (1 revision)
  14. Count median diameter‏‎ (1 revision)
  15. Reference parameter value‏‎ (1 revision)
  16. ICRP Publication 30 (Part 1)‏‎ (1 revision)
  17. Deposition‏‎ (1 revision)
  18. ICRP Publication 90‏‎ (1 revision)
  19. ICRP Publication 39‏‎ (1 revision)
  20. Digital breast tomosynthesis‏‎ (1 revision)
  21. ICRP Publication 53‏‎ (1 revision)
  22. Size-specific dose estimate‏‎ (1 revision)
  23. ICRP Publication 68‏‎ (1 revision)
  24. Specific absorbed fraction‏‎ (1 revision)
  25. ICRP Publication 82‏‎ (1 revision)
  26. Surface contamination‏‎ (1 revision)
  27. Excess absolute risk‏‎ (1 revision)
  28. Exposure pathway‏‎ (1 revision)
  29. Translocation‏‎ (1 revision)
  30. Multistage carcinogenesis model‏‎ (1 revision)
  31. Functional subunits‏‎ (1 revision)
  32. Activity median aerodynamic diameter‏‎ (1 revision)
  33. Ground-level enhancement‏‎ (1 revision)
  34. Phantom‏‎ (1 revision)
  35. ICRP Publication 101a‏‎ (1 revision)
  36. ICRP Publication 114‏‎ (1 revision)
  37. ICRP Publication 129‏‎ (1 revision)
  38. ICRP Publication 143‏‎ (1 revision)
  39. Compartment (environmental)‏‎ (1 revision)
  40. Ras‏‎ (1 revision)
  41. ICRP Publication 18‏‎ (1 revision)
  42. Cross section‏‎ (1 revision)
  43. Reference phantom‏‎ (1 revision)
  44. ICRP Publication 30 (Part 2)‏‎ (1 revision)
  45. ICRP Publication 91‏‎ (1 revision)
  46. ICRP Publication 4‏‎ (1 revision)
  47. ICRP Publication 54‏‎ (1 revision)
  48. Slice‏‎ (1 revision)
  49. ICRP Publication 69‏‎ (1 revision)
  50. ICRP Publication 83‏‎ (1 revision)
  51. Threshold level‏‎ (1 revision)
  52. Organ at risk‏‎ (1 revision)
  53. Homologous recombination‏‎ (1 revision)
  54. Authorised discharge‏‎ (1 revision)
  55. ICRP Publication 101b‏‎ (1 revision)
  56. Principles of protection‏‎ (1 revision)
  57. ICRP Publication 115‏‎ (1 revision)
  58. Radiation-induced second cancer‏‎ (1 revision)
  59. ICRP Publication 13‏‎ (1 revision)
  60. Clinical audit‏‎ (1 revision)
  61. ICRP Publication 144‏‎ (1 revision)
  62. Rb‏‎ (1 revision)
  63. ICRP Publication 19‏‎ (1 revision)
  64. Reference value‏‎ (1 revision)
  65. ICRP Publication 30 (Part 3)‏‎ (1 revision)
  66. Derived consideration reference level‏‎ (1 revision)
  67. ICRP Publication 92‏‎ (1 revision)
  68. ICRP Publication 40‏‎ (1 revision)
  69. ICRP Publication 55‏‎ (1 revision)
  70. Dose conversion convention‏‎ (1 revision)
  71. Informed consent‏‎ (1 revision)
  72. ICRP Publication 7‏‎ (1 revision)
  73. Spongiosa‏‎ (1 revision)
  74. ICRP Publication 84‏‎ (1 revision)
  75. Exclusion‏‎ (1 revision)
  76. Marrow cellularity‏‎ (1 revision)
  77. Multitarget equation‏‎ (1 revision)
  78. Acute exposure‏‎ (1 revision)
  79. Allometry‏‎ (1 revision)
  80. Pilomatricoma‏‎ (1 revision)
  81. ICRP Publication 102‏‎ (1 revision)
  82. ICRP Publication 116‏‎ (1 revision)
  83. Radiation-induced secondary malignancy‏‎ (1 revision)
  84. ICRP Publication 130‏‎ (1 revision)
  85. Radiological attack‏‎ (1 revision)
  86. ICRP Publication 145‏‎ (1 revision)
  87. Reactive oxygen species‏‎ (1 revision)
  88. ICRP Publication 2‏‎ (1 revision)
  89. Reference worker‏‎ (1 revision)
  90. ICRP Publication 30 (Part 4)‏‎ (1 revision)
  91. Derived investigation level‏‎ (1 revision)
  92. ICRP Publication 93‏‎ (1 revision)
  93. ICRP Publication 41‏‎ (1 revision)
  94. Directional dose equivalent‏‎ (1 revision)
  95. ICRU 4-element tissue‏‎ (1 revision)
  96. ICRP Publication 56‏‎ (1 revision)
  97. Dose conversion factor‏‎ (1 revision)
  98. ICRP Publication 70‏‎ (1 revision)
  99. Effect modifier‏‎ (1 revision)
  100. ICRP Publication 85‏‎ (1 revision)
  101. Endosteum‏‎ (1 revision)
  102. System of radiological protection‏‎ (1 revision)
  103. Time-resolved computed tomography‏‎ (1 revision)
  104. Mutation component‏‎ (1 revision)
  105. Waste management‏‎ (1 revision)
  106. Normal tissue complication probability‏‎ (1 revision)
  107. Biological half-life‏‎ (1 revision)
  108. ICRP Publication 117‏‎ (1 revision)
  109. ICRP Publication 131‏‎ (1 revision)
  110. Radiological controlled area‏‎ (1 revision)
  111. ICRP Publication 146‏‎ (1 revision)
  112. Concentration ratio‏‎ (1 revision)
  113. ICRP Publication 20‏‎ (1 revision)
  114. Referrer‏‎ (1 revision)
  115. ICRP Publication 30 (Supplement A to Part 3)‏‎ (1 revision)
  116. Derived limit‏‎ (1 revision)
  117. ICRP Publication 94‏‎ (1 revision)
  118. ICRP Publication 42‏‎ (1 revision)
  119. ICRU sphere‏‎ (1 revision)
  120. ICRP Publication 57‏‎ (1 revision)
  121. ICRP Publication 71‏‎ (1 revision)
  122. ICRP Publication 86‏‎ (1 revision)
  123. Treatment preparation in radiotherapy‏‎ (1 revision)
  124. Notification value‏‎ (1 revision)
  125. Other (systemic) tissues‏‎ (1 revision)
  126. Human Alimentary Tract Model‏‎ (1 revision)
  127. ICRP Publication 104‏‎ (1 revision)
  128. Biomarker‏‎ (1 revision)
  129. ICRP Publication 132‏‎ (1 revision)
  130. Clonogenic surviving fraction‏‎ (1 revision)
  131. ICRP Publication 147‏‎ (1 revision)
  132. Cone beam computed tomography‏‎ (1 revision)
  133. ICRP Publication 21‏‎ (1 revision)
  134. Region‏‎ (1 revision)
  135. Retrievability‏‎ (2 revisions)
  136. Immune system‏‎ (2 revisions)
  137. Institutional control‏‎ (2 revisions)
  138. Stakeholder‏‎ (2 revisions)
  139. Environmental radiation protection‏‎ (2 revisions)
  140. Tachycardia‏‎ (2 revisions)
  141. Exemption level‏‎ (2 revisions)
  142. Tissue equivalent material‏‎ (2 revisions)
  143. Myocardial stress test‏‎ (2 revisions)
  144. Oversight‏‎ (2 revisions)
  145. Projected dose‏‎ (2 revisions)
  146. Co-expertise‏‎ (2 revisions)
  147. Radionuclides of natural origin‏‎ (2 revisions)
  148. Connective tissue‏‎ (2 revisions)
  149. Recovery (cellular or tissue)‏‎ (2 revisions)
  150. DRL process‏‎ (2 revisions)
  151. Reversibility‏‎ (2 revisions)
  152. In vivo radiobioassay‏‎ (2 revisions)
  153. Solar particle event‏‎ (2 revisions)
  154. Effective dose equivalent‏‎ (2 revisions)
  155. Existing exposure situation‏‎ (2 revisions)
  156. Gastroschisis‏‎ (2 revisions)
  157. Worker‏‎ (2 revisions)
  158. Nuclear track detectors‏‎ (2 revisions)
  159. Angiogenesis‏‎ (2 revisions)
  160. Hyperbaric oxygen‏‎ (2 revisions)
  161. Bioturbation‏‎ (2 revisions)
  162. Cardioverter-defibrillator‏‎ (2 revisions)
  163. Radiation safety officer‏‎ (2 revisions)
  164. Radioresponsiveness‏‎ (2 revisions)
  165. Consequential late effects‏‎ (2 revisions)
  166. Recovery responder‏‎ (2 revisions)
  167. Rehabilitation of living conditions‏‎ (2 revisions)
  168. Right to know‏‎ (2 revisions)
  169. Incidence‏‎ (2 revisions)
  170. Solar wind‏‎ (2 revisions)
  171. Epithelium‏‎ (2 revisions)
  172. Target tissue‏‎ (2 revisions)
  173. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  174. Acceptance test‏‎ (2 revisions)
  175. Gastrulation‏‎ (2 revisions)
  176. Working level‏‎ (2 revisions)
  177. OLINDA/EXM‏‎ (2 revisions)
  178. Habitual mouth breather‏‎ (2 revisions)
  179. Annihilation photons‏‎ (2 revisions)
  180. Particle radiance‏‎ (2 revisions)
  181. Hyperfractionation‏‎ (2 revisions)
  182. Bone marrow‏‎ (2 revisions)
  183. Protection strategy‏‎ (2 revisions)
  184. Radiation source‏‎ (2 revisions)
  185. Cohort study‏‎ (2 revisions)
  186. Radiosensitiser‏‎ (2 revisions)
  187. DRL value‏‎ (2 revisions)
  188. Rigidity‏‎ (2 revisions)
  189. Dose-length product‏‎ (2 revisions)
  190. Security‏‎ (2 revisions)
  191. Incident‏‎ (2 revisions)
  192. Intermediate level waste‏‎ (2 revisions)
  193. Stenosis‏‎ (2 revisions)
  194. Equieffective dose‏‎ (2 revisions)
  195. Local DRL‏‎ (2 revisions)
  196. Expanded and aligned radiation field‏‎ (2 revisions)
  197. Tolerability‏‎ (2 revisions)
  198. Medical exposure‏‎ (2 revisions)
  199. Naturally occurring radioactive material‏‎ (2 revisions)
  200. Adventitious‏‎ (2 revisions)
  201. Working level month‏‎ (2 revisions)
  202. Habitual nose breather‏‎ (2 revisions)
  203. Hypertrophic cardiomyopathy‏‎ (2 revisions)
  204. Background dose (rate)‏‎ (2 revisions)
  205. Radiosensitivity, cellular‏‎ (2 revisions)
  206. Containment‏‎ (2 revisions)
  207. Detriment‏‎ (2 revisions)
  208. Dose-rate effect‏‎ (2 revisions)
  209. Inclusiveness‏‎ (2 revisions)
  210. Source-related‏‎ (2 revisions)
  211. Internal conversion electron‏‎ (2 revisions)
  212. Electron-capture decay‏‎ (2 revisions)
  213. LD 50/30‏‎ (2 revisions)
  214. Telangiectasia‏‎ (2 revisions)
  215. Member of the public‏‎ (2 revisions)
  216. Fluoroscopically or computed tomography guided interventions‏‎ (2 revisions)
  217. Unattached fraction‏‎ (2 revisions)
  218. Necrosis‏‎ (2 revisions)
  219. Patient entrance reference point‏‎ (2 revisions)
  220. Hypoplasia‏‎ (2 revisions)
  221. Backscatter detection system‏‎ (2 revisions)
  222. Potential recoverability correction factor‏‎ (2 revisions)
  223. Bradycardia‏‎ (2 revisions)
  224. Protective action guide‏‎ (2 revisions)
  225. Radiation worker‏‎ (2 revisions)
  226. Decay constant‏‎ (2 revisions)
  227. Self-help protection‏‎ (2 revisions)
  228. Individual-related‏‎ (2 revisions)
  229. Dose of record Hp (10)‏‎ (2 revisions)
  230. Electrophysiology‏‎ (2 revisions)
  231. Storage‏‎ (2 revisions)
  232. Track structure‏‎ (2 revisions)
  233. Mendelian diseases‏‎ (2 revisions)
  234. Accreditation‏‎ (2 revisions)
  235. Neurological syndrome‏‎ (2 revisions)
  236. Genomic integrity‏‎ (2 revisions)
  237. Occupational exposure‏‎ (2 revisions)
  238. Hazard‏‎ (2 revisions)
  239. Peak skin dose‏‎ (2 revisions)
  240. Bragg peak‏‎ (2 revisions)
  241. Radioactive dispersion device‏‎ (2 revisions)
  242. Radon: Units of Measure‏‎ (2 revisions)
  243. Coronary heart disease‏‎ (2 revisions)
  244. Reference air kerma‏‎ (2 revisions)
  245. Decommissioning‏‎ (2 revisions)
  246. ICRP Task Groups on Radiological Protection in Healthcare‏‎ (2 revisions)
  247. Dose-threshold‏‎ (2 revisions)
  248. Individual decontamination‏‎ (2 revisions)
  249. Subcutaneous tissue‏‎ (2 revisions)
  250. Low dose rate‏‎ (2 revisions)
  251. Transfer compartment‏‎ (2 revisions)
  252. Mitigation‏‎ (2 revisions)
  253. Fractional absorption in the gastrointestinal tract‏‎ (2 revisions)
  254. Action Level‏‎ (2 revisions)
  255. Upper reference levels‏‎ (2 revisions)
  256. Neurovascular syndrome‏‎ (2 revisions)
  257. Health Surveillance‏‎ (2 revisions)
  258. Pelagic‏‎ (2 revisions)
  259. Basal cell‏‎ (2 revisions)
  260. Practical radiological protection culture‏‎ (2 revisions)
  261. Branching fraction‏‎ (2 revisions)
  262. Chronic exposure‏‎ (2 revisions)
  263. Radioactive source‏‎ (2 revisions)
  264. Colony‏‎ (2 revisions)
  265. Cosmic Radiation in Aviation‏‎ (2 revisions)
  266. Decontamination‏‎ (2 revisions)
  267. Relocation‏‎ (2 revisions)
  268. Diastasis‏‎ (2 revisions)
  269. Risk coefficient‏‎ (2 revisions)
  270. Individual monitoring‏‎ (2 revisions)
  271. Dose per unit intake coefficient‏‎ (2 revisions)
  272. Source term‏‎ (2 revisions)
  273. Emergency‏‎ (2 revisions)
  274. Latent time/period or latency interval‏‎ (2 revisions)
  275. Low level waste‏‎ (2 revisions)
  276. Exposure, external or internal‏‎ (2 revisions)
  277. Graft vs host disease‏‎ (2 revisions)
  278. Air-kerma, incident‏‎ (2 revisions)
  279. Heliosphere‏‎ (2 revisions)
  280. Qualified expert‏‎ (2 revisions)
  281. Class SR-0 gases‏‎ (2 revisions)
  282. Radioactive substance‏‎ (2 revisions)
  283. Reference biokinetic model‏‎ (2 revisions)
  284. Decontamination factor‏‎ (2 revisions)
  285. Remedial action‏‎ (2 revisions)
  286. ICRPædia Guide to Dose Coefficients‏‎ (2 revisions)
  287. Dose rate‏‎ (2 revisions)
  288. Intervention Level‏‎ (2 revisions)
  289. Emergency exposure situation‏‎ (2 revisions)
  290. Substantial radiation dose level‏‎ (2 revisions)
  291. Erythropoietin‏‎ (2 revisions)
  292. Exposure (in the context of inhalation)‏‎ (2 revisions)
  293. Transfer rate‏‎ (2 revisions)
  294. Multi-detector computed tomography‏‎ (2 revisions)
  295. Fractionation and dose delivery patterns‏‎ (2 revisions)
  296. Percutaneous coronary intervention‏‎ (2 revisions)
  297. Prevailing circumstances‏‎ (2 revisions)
  298. Broad beam therapy irradiation technique‏‎ (2 revisions)
  299. Class SR-1 gases‏‎ (2 revisions)
  300. Committed effective dose‏‎ (2 revisions)
  301. Radon Recommendations for Authorities‏‎ (2 revisions)
  302. Cost-benefit analysis‏‎ (2 revisions)
  303. Reference individual‏‎ (2 revisions)
  304. Remediation‏‎ (2 revisions)
  305. Dichotomous‏‎ (2 revisions)
  306. Risk of Exposure to Radon‏‎ (2 revisions)
  307. Dose rate effectiveness factor‏‎ (2 revisions)
  308. South Atlantic anomaly‏‎ (2 revisions)
  309. Interventional procedure‏‎ (2 revisions)
  310. Emergency plan‏‎ (2 revisions)
  311. Ethics‏‎ (2 revisions)
  312. Lymphatic system‏‎ (2 revisions)
  313. ALARA‏‎ (2 revisions)
  314. Transforming growth factor‏‎ (2 revisions)
  315. Hierarchical tissues‏‎ (2 revisions)
  316. Area monitoring‏‎ (2 revisions)
  317. Pericarditis‏‎ (2 revisions)
  318. Benthic‏‎ (2 revisions)
  319. Principle of application of dose limits‏‎ (2 revisions)
  320. Bronchial region‏‎ (2 revisions)
  321. Class SR-2 gases‏‎ (2 revisions)
  322. Radioactivity‏‎ (2 revisions)
  323. Committed equivalent dose‏‎ (2 revisions)
  324. Radon Recommendations for Workplaces‏‎ (2 revisions)
  325. Reference level‏‎ (2 revisions)
  326. Deontological Ethics‏‎ (2 revisions)
  327. Repopulation‏‎ (2 revisions)
  328. Differentiation‏‎ (2 revisions)
  329. Routine monitoring‏‎ (2 revisions)
  330. ICRPædia Guide to Radon‏‎ (2 revisions)
  331. Special (non-routine) monitoring‏‎ (2 revisions)
  332. Lifetime risk‏‎ (2 revisions)
  333. Macrophage colony stimulating factor‏‎ (2 revisions)
  334. Multiplicative risk projection model‏‎ (2 revisions)
  335. Activity‏‎ (2 revisions)
  336. High level waste‏‎ (2 revisions)
  337. Clearance‏‎ (2 revisions)
  338. Representative organism (non-human biota)‏‎ (2 revisions)
  339. ICRPædia Guide to the Basics of Ionising Radiation‏‎ (2 revisions)
  340. Dose constraint‏‎ (2 revisions)
  341. Early normal tissue responses‏‎ (2 revisions)
  342. Threshold dose for tissue reactions‏‎ (2 revisions)
  343. Magnetosphere‏‎ (2 revisions)
  344. Beta-minus decay‏‎ (2 revisions)
  345. Clearance level‏‎ (2 revisions)
  346. Radiographer‏‎ (2 revisions)
  347. Representative person‏‎ (2 revisions)
  348. Safety‏‎ (2 revisions)
  349. Dose conversion coefficient‏‎ (2 revisions)
  350. Edema‏‎ (2 revisions)
  351. Specific effective energy‏‎ (2 revisions)
  352. Limitation of dose‏‎ (2 revisions)
  353. Excess relative risk‏‎ (2 revisions)
  354. Exposure situation‏‎ (2 revisions)
  355. Transmission detection system‏‎ (2 revisions)
  356. Multistage tumorigenesis‏‎ (2 revisions)
  357. Non-sphericity parameter‏‎ (2 revisions)
  358. Growth factor‏‎ (2 revisions)
  359. Alimentary tract transfer factor‏‎ (2 revisions)
  360. Pharynx‏‎ (2 revisions)
  361. Beta-plus decay‏‎ (2 revisions)
  362. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  363. Cumulative dose‏‎ (2 revisions)
  364. Reproductive integrity‏‎ (2 revisions)
  365. Safety case‏‎ (2 revisions)
  366. Slow repair‏‎ (2 revisions)
  367. Effect Dose 50‏‎ (2 revisions)
  368. Isotropic geometry‏‎ (2 revisions)
  369. Endogeneous excretion‏‎ (2 revisions)
  370. Lineal energy‏‎ (2 revisions)
  371. Thyroid blocking‏‎ (2 revisions)
  372. Exposure to Radon at Home‏‎ (2 revisions)
  373. Transparency‏‎ (2 revisions)
  374. GATA binding protein 2‏‎ (2 revisions)
  375. Waste disposal‏‎ (2 revisions)
  376. Non-targeted effects‏‎ (2 revisions)
  377. Hormones‏‎ (2 revisions)
  378. Authorization‏‎ (2 revisions)
  379. Procedural values‏‎ (2 revisions)
  380. Clonogenic cells‏‎ (2 revisions)
  381. Curie‏‎ (2 revisions)
  382. Residual dose‏‎ (2 revisions)
  383. Safety culture‏‎ (2 revisions)
  384. Solar cosmic radiation‏‎ (2 revisions)
  385. Inhalability‏‎ (2 revisions)
  386. Spontaneous fission‏‎ (2 revisions)
  387. Itinerant (radiation) worker‏‎ (2 revisions)
  388. Linear-non-threshold model‏‎ (2 revisions)
  389. Trapped particles‏‎ (2 revisions)
  390. Acute radiation syndrome‏‎ (2 revisions)
  391. Orphan source‏‎ (2 revisions)
  392. Hounsfield unit‏‎ (2 revisions)
  393. Authorized limit‏‎ (2 revisions)
  394. Planned exposure situation‏‎ (2 revisions)
  395. Progenitor cell‏‎ (2 revisions)
  396. Cardiac arrhythmias‏‎ (2 revisions)
  397. Radiation belt‏‎ (2 revisions - redirect page)
  398. Clonogenic survival‏‎ (2 revisions)
  399. Reasonableness‏‎ (2 revisions)
  400. Cytokines‏‎ (2 revisions)
  401. Respiratory protection‏‎ (2 revisions)
  402. Disposal‏‎ (2 revisions)
  403. Scintigraphy‏‎ (2 revisions)
  404. Dose criteria‏‎ (2 revisions)
  405. Solar cycle‏‎ (2 revisions)
  406. Inner bremsstrahlung‏‎ (2 revisions)
  407. Environmental exposure‏‎ (2 revisions)
  408. Systemic model‏‎ (2 revisions)
  409. Linear-quadratic dose response model‏‎ (2 revisions)
  410. Exempt waste‏‎ (2 revisions)
  411. Time factor‏‎ (2 revisions)
  412. Myocardial perfusion‏‎ (2 revisions)
  413. Adaptive response‏‎ (2 revisions)
  414. What is Radon?‏‎ (2 revisions)
  415. Alveolar-interstitial region‏‎ (2 revisions)
  416. Autoimmune disease‏‎ (2 revisions)
  417. Platelet-derived growth factor‏‎ (2 revisions)
  418. ICRP Publication 118‏‎ (2 revisions)
  419. Cardiac valve diseases‏‎ (2 revisions)
  420. Radiation modifier‏‎ (2 revisions)
  421. Radiological protection principles‏‎ (2 revisions)
  422. Dose equivalent‏‎ (3 revisions)
  423. Field-size effect (Volume effect)‏‎ (3 revisions)
  424. Gastrointestinal syndrome‏‎ (3 revisions)
  425. Wisdom‏‎ (3 revisions)
  426. Biomedical research volunteer‏‎ (3 revisions)
  427. Cardiomyopathy‏‎ (3 revisions)
  428. Dose limit‏‎ (3 revisions)
  429. Target region‏‎ (3 revisions)
  430. Flexible tissues‏‎ (3 revisions)
  431. Guide to the System of Radiological Protection‏‎ (3 revisions)
  432. Autonomy‏‎ (3 revisions)
  433. Dose‏‎ (3 revisions)
  434. Dose limits‏‎ (3 revisions)
  435. Fluence‏‎ (3 revisions)
  436. Constancy test‏‎ (3 revisions)
  437. DS02‏‎ (3 revisions)
  438. Fluoroscopically guided interventions‏‎ (3 revisions)
  439. Annual dose‏‎ (3 revisions)
  440. Potential exposure‏‎ (3 revisions)
  441. Rigidity threshold‏‎ (3 revisions)
  442. Dose of record (E)‏‎ (3 revisions)
  443. Low Earth orbit‏‎ (3 revisions)
  444. Accountability‏‎ (3 revisions)
  445. X ray‏‎ (3 revisions)
  446. Half-life, physical‏‎ (3 revisions)
  447. Cell death‏‎ (3 revisions)
  448. Contamination‏‎ (3 revisions)
  449. Exponential survival curve‏‎ (3 revisions)
  450. Unsealed source‏‎ (3 revisions)
  451. Xerostomia‏‎ (3 revisions)
  452. Annual limit on intake‏‎ (3 revisions)
  453. Dose per content function‏‎ (3 revisions)
  454. Interphase death‏‎ (3 revisions)
  455. Equity‏‎ (3 revisions)
  456. Test‏‎ (3 revisions)
  457. Graded approach‏‎ (3 revisions)
  458. Public exposure‏‎ (3 revisions)
  459. Fractionation‏‎ (3 revisions)
  460. Uptake‏‎ (3 revisions)
  461. Active (red) bone marrow‏‎ (3 revisions)
  462. Utilitarian ethics‏‎ (3 revisions)
  463. Granulocyte-macrophage colony-stimulating factor‏‎ (3 revisions)
  464. Operational quantity‏‎ (3 revisions)
  465. Value judgement‏‎ (3 revisions)
  466. Granulocyte colony-stimulating factor‏‎ (3 revisions)
  467. Coster-Kronig transition‏‎ (3 revisions)
  468. Emergency preparedness‏‎ (3 revisions)
  469. Valvular heart disease‏‎ (3 revisions)
  470. Gray‏‎ (3 revisions)
  471. Personal dose equivalent‏‎ (3 revisions)
  472. Principle of justification‏‎ (3 revisions)
  473. Radiofrequency ablation‏‎ (3 revisions)
  474. Iso-effect plots‏‎ (3 revisions)
  475. Emergency procedures‏‎ (3 revisions)
  476. Lifetime risk estimates‏‎ (3 revisions)
  477. Absolute risk‏‎ (3 revisions)
  478. Virtue ethics‏‎ (3 revisions)
  479. Auger transition‏‎ (3 revisions)
  480. Bystander effect‏‎ (3 revisions)
  481. Derived air concentration‏‎ (3 revisions)
  482. Dignity‏‎ (3 revisions)
  483. Isomers‏‎ (3 revisions)
  484. Employer‏‎ (3 revisions)
  485. Activity median thermodynamic diameter‏‎ (3 revisions)
  486. Voxel phantom‏‎ (3 revisions)
  487. Radiological Protection in Healthcare‏‎ (3 revisions - redirect page)
  488. Complex tissues‏‎ (3 revisions)
  489. Growth fraction‏‎ (3 revisions)
  490. Organ dose equivalent‏‎ (3 revisions)
  491. Excretion rate (instantaneous)‏‎ (3 revisions)
  492. Extrathoracic airways‏‎ (3 revisions)
  493. Galactic cosmic radiation‏‎ (3 revisions)
  494. Growth hormone (somatotropin)‏‎ (3 revisions)
  495. ICRP Publication 103‏‎ (3 revisions)
  496. Spread-out Bragg peak‏‎ (3 revisions)
  497. Fairness‏‎ (3 revisions)
  498. Absorption‏‎ (3 revisions)
  499. Gamma ray‏‎ (3 revisions)
  500. Recovery‏‎ (3 revisions)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)